upper extremity of these elderly patients with very fair skin. The preferred treatment was physical destruction of the lesions instead of noninvasive topical 

PSS3 THE PROFILE OF SOLAR EXPOSITION AND USE OF SUNSCREENING AGENTS USE OF PATIENTS FROM SÃO PAULO CITY WITH ACTINIC KERATOSIS (AK)

OBJECTIVES: Actinic keratoses are common dysplastic epidermal lesions which occur in pale-skinned individuals who are chronically exposed to intense sunlight. The aim of this research was to describe the Brazilian profile of solar exposition and the sunscreening agents use in patients with AK. METHODS: A two months health survey was performed in São Paulo city in which 10 dermatologists registered the profile of solar exposition and the sunscreening agents use of a sample of patients with AK. RESULTS: Of a total of 4961 patients, 269 (5,4%) patients were diagnosed with AK of which 58% were females. The mean age of the patients was 65 years old. Before AK diagnosis 91% of the patients exposed themselves to the sun mainly for leisure during weekends and only 26% used sunscreening agents. After AK diagnosis 43% of the patients still had the habit of solar exposition, however they changed the type of sunscreening agents. The sun protection factor (SPF) most used before of the diagnosis was SPF15 (44%) and SPF30 (38%), changing to SPF30 (40%) and SPF60 (33%) after the diagnosis. CONCLUSIONS: This data suggest that the São Paulo city population with actinic keratosis presents the habit of leisure solar exposition with insufficient use of sunscreening agents. The use of sunscreening agents increases after the diagnosis of the disease.

URINARY/KIDNEY DISORDERS – Clinical Outcomes Studies

PUK1 COMPARATIVE EFFICACY AND SAFETY OF TREATMENTS FOR THE MANAGEMENT OF OVERACTIVE BLADDER: A SYSTEMATIC LITERATURE REVIEW AND MIXED TREATMENT COMPARISON

Maman K1, Abaila E2, Nazir J3, Desroziers K2, Neine M2, Siddiqui E4, Odeyemi P5, Hakim M5


OBJECTIVES: Overactive bladder (OAB) treatment guidelines recommend antimuscarinics as first-line pharmacologic therapy. Mirabegron is a first-in-class beta-3 adrenoceptor agonist which is licensed for the treatment of OAB and has shown to be well tolerated and effective in the treatment of OAB symptoms. A systematic literature review and Mixed Treatment Comparisons (MTC) were performed to assess the efficacy and tolerability of OAB medications in patients with OAB. METHODS: Included randomised controlled trials (RCTs) estimating changes in symptoms (micturition frequency, incontinence and urgency incontinence episodes) and probabilities of the most frequently reported adverse events associated with current OAB medications. Literature searches were performed to assess the efficacy and tolerability of OAB medications, and more events associated with current OAB medications. Literature searches were performed to assess the efficacy and tolerability of OAB medications, and more

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES

PUEK EVALUATION OF COMPARATIVE COST ANALYSIS OF RENAL REPLACEMENT THERAPIES